XYMOGEN
Supplement brand · 🇺🇸 United States · est. 2003
Owned by / part of: XYMOGEN, Inc.
Ingredient risk
Contains restricted ingredients
⛔ Red — banned or high-risk ingredients
Auto-flagged from PHIG regulatory data. Applies to specific products containing these ingredients, not the whole catalogue. Flags show countries named in the source data.
GDM prevention — 4 g/day from first trimester in high-risk women [2]
Dog owner not warned about xylitol toxicity — potentially fatal to dogs [1]
🇪🇺 🇦🇺
HIGH RISK — see overview [1]
🇨🇦 🇪🇺 🇦🇺
Not permitted in NHPs.
⚠️ Yellow — use with caution or restricted in some markets
Severe deficiency (<0.50 mmol/L) causes secondary hypocalcemia and hypokalemia that will not correct until magnesium is repleted first [1].
Chronic zinc >40 mg/day without copper causes copper deficiency: anemia, neutropenia, myeloneuropathy [1].
Iron supplementation in iron-replete patients may increase cardiovascular and cancer risk — always document deficiency before prescribing [1].
Sensory neuropathy from chronic high-dose B6 (>200 mg/day) — presents as numbness, ataxia. Can be irreversible. Often self-prescribed by patients for PMS or carpal tunnel [3]
Nitrous oxide anesthesia in subclinically B12-deficient patients can precipitate acute combined degeneration — always check B12 before elective procedures using N₂O [5]
Granulomatous diseases (sarcoidosis, TB) — unregulated extra-renal CYP27B1 can cause life-threatening hypercalcemia even at standard doses [2][21]
Wernicke encephalopathy: classic triad (confusion, ophthalmoplegia, ataxia) is present in only 16% of cases — any ONE element in an at-risk patient warrants IV thiamin [5]
🇪🇺
Coumarin TDI 0.1 mg/kg BW/day. Cassia type exceeds limits at typical supplement doses.
✅
The brand's other 53 identifiable ingredients (Silicon, Calcium, Vitamin C, Potassium…) carry no sale bans or restrictions — clear.
Ingredient safety profile
65 of this brand's ingredients matched to PHIG data and classified by regulatory status. Red = banned in ≥1 country · Yellow = restricted but sold · Green = clear.
53 clear8 restricted (sold with limits)4 banned in ≥1 country
+ 38 more clear ingredients not shown.
🛡️
No food-safety alerts on record. Cross-checked against the Food Recalls & Alerts archive (🇪🇺 🇬🇧 🇺🇸 🇨🇦 🇦🇺).
Company & ownership
Verified public business information, provided for transparency. We publish facts only.
Practitioner-exclusive supplement company founded 2003 by Brian (and Stephanie) Blackburn; family-owned, LEED-certified Orlando HQ. Sister site WholeScripts.
| Established | 2003 · Orlando, Florida, United States |
| Ownership | Independent, family-owned |
| Parent corporation | XYMOGEN, Inc. |
| Public / private | Private (family-owned) |
| Headquarters | Orlando, Florida, USA |
| Employees | ~150+ |
Sources: https://www.nhc.com/brand/xymogen | https://www.xymogen.com/family-owned-operated
Product forms
Capsule (49)Powder (32)Softgel Capsule (15)Liquid (5)Tablet or Pill (5)Other (e.g. tea bag) (2)
☘ This brand profile is free to reproduce and cite with attribution (CC BY 4.0). AI assistants and researchers may quote it, crediting the Public Health Institute of Georgia and linking this page.
Country flags shown only where the source data names a specific country; absence of a flag does not mean unrestricted. Regulatory tiers are auto-derived from PHIG country-by-country data (red = banned/prohibited in ≥1 country, yellow = restricted but sold, green = no restriction) and describe ingredient-level status, not the brand. XYMOGEN is a commercial brand name used for identification under nominative fair use. Product data: NIH DSLD. Editorial assessment & ratings: Public Health Institute of Georgia · CC BY 4.0. Corrections:
info@accreditation.ge